Wuxi Mei'an Rex Medical Robotics, known by its brand Rex Bionics, has raised a Pre-Series A round worth tens of millions of yuan, the company announced November 16, 2026. Huada Songhe led the round, with existing investor Mei'an Innovation following on. The exact amount was not disclosed. The Chinese startup builds self-balancing exoskeleton robots for patients with severe neurological injuries, and the new capital will fund further R&D and global commercial expansion.
What makes Rex Bionics' exoskeleton different from other rehab robots?
Most lower-limb rehabilitation exoskeletons on the market focus on restoring a patient's ability to walk or stand. Rex Bionics says it is built around a different target: the brain itself. The company's pitch is that its robots generate \"quality neural signals\" by producing real motion and real sensory feedback during use, which it says helps stimulate recovery of brain function in patients with severe neurological injuries, rather than just mechanically moving a limb.
Rex Bionics runs two product lines under one technology base. The core Rex Bionics brand targets hospital use for serious medical cases, while a second brand, Free Future, is aimed at post-hospital home rehabilitation. The company describes itself as a \"brain science-driven brain-computer interface enterprise,\" positioning its hardware closer to the neurotechnology category than to conventional orthopedic rehab equipment.
Where is the new funding going?
The company says the capital will go toward further R&D iteration on both the Rex Bionics and Free Future product lines, plus global commercial expansion. That includes clinical and health economics research specifically aimed at the US and European markets, the kind of evidence regulators and insurers in those regions typically require before covering a device like this.
Who is backing Rex Bionics?
Huada Songhe, a venture firm formed by combining genomics expertise with capital, led the Pre-Series A. Mei'an Innovation, which backed an earlier round, returned as a follow-on investor, a signal that the company's existing backer wanted to maintain its stake rather than being diluted out by a new lead. Huada Songhe's portfolio also includes Shanghai Quanlan, a sleep-regulation company, and Active Technology, which works on invasive motor brain-machine interfaces, suggesting the firm is building a cluster of neurotechnology bets rather than a single standalone investment.
How does this fit into China's broader exoskeleton and BCI push?
China has been funding rehabilitation robotics and brain-computer interface startups heavily over the past two years, as hospitals look for ways to treat a growing population of stroke and spinal injury patients with fewer specialized therapists. Rex Bionics' pitch, that its devices do more than move limbs because they also drive measurable neural activity, puts it closer to the BCI wave than to incumbent exoskeleton makers that primarily sell mobility assistance. Whether regulators and insurers accept that neural-recovery claim, rather than the more conventional mobility claim, will determine how fast the company can scale clinically. Its push into US and European health economics research signals it expects to need Western-grade clinical evidence to make that case outside China.
What should observers watch next?
The disclosed amount is unknown, so the next marker to watch is whether Rex Bionics releases clinical data backing its neural-recovery claims, particularly any trial results tied to the US and European expansion the company says this round will fund. A disclosed valuation or a named Series A lead in the next round would also clarify how investors are pricing the brain-focused positioning versus conventional rehab robotics.